Mitochondrial Quality Control in the Heart: New Drug Targets for Cardiovascular Disease

Chang-Myung Oh MD, PhD,1*, Dongryeol Ryu PhD2,3,4*, Sungsoo Cho MD, PhD5, and Yangsoo Jang MD, PhD6

1Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Korea
2Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea
3Biomedical institute for Convergence at SKKU (BICS), Sungkyunkwan University (SKKU), Suwon, Korea
4Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
5Division of Cardiovascular Medicine, Department of Internal Medicine, Dankook University College of Medicine, Dankook University Hospital, Cheonan, Korea
6Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

ABSTRACT

Despite considerable efforts to prevent and treat cardiovascular disease (CVD), it has become the leading cause of death worldwide. Cardiac mitochondria are crucial cell organelles responsible for creating energy-rich ATP and mitochondrial dysfunction is the root cause for developing heart failure. Therefore, maintenance of mitochondrial quality control (MQC) is an essential process for cardiovascular homeostasis and cardiac health. In this review, we describe the major mechanisms of MQC system, such as mitochondrial unfolded protein response and mitophagy. Moreover, we describe the results of MQC failure in cardiac mitochondria. Furthermore, we discuss the prospects of 2 drug candidates, urolithin A and spermidine, for restoring mitochondrial homeostasis to treat CVD.

Keywords: Mitochondrial quality control; Heart; Urolithin A; Spermidine

INTRODUCTION

The mammalian heart is highly oxidative, consuming high levels of oxygen to generate adenosine triphosphate (ATP) for myocyte contraction and relaxation.1,2 Mitochondria are highly dynamic cell organelles that take part in a wide-range of functions. In cardiac myocytes, mitochondria are crucial for heart function through oxidative ATP generation. In addition to energy production, mitochondria play a role in fatty acid synthesis, amino acid production, heme synthesis, iron-sulfur cluster biogenesis, and act as a signaling hub for innate immunity and cell death.3 Mitochondrial dysfunction leads to energetic dysfunction, oxidative stress, calcium dysregulation, and cardiomyocyte death.3 Therefore, mitochondrial dysfunction is currently being considered as a potential therapeutic target.

To achieve mitochondrial homeostasis and maintain a healthy mitochondrial status, cardiac myocytes have quality control mechanisms known as mitochondrial quality control (MQC) systems.4 For the maintenance of mitochondrial protein homeostasis, mitochondria contain...
Conflict of Interest
The authors have no financial conflicts of interest.

Author Contributions
Conceptualization: Oh CM, Ryu D, Cho S, Jang Y; Funding acquisition: Oh CM, Ryu D; Methodology: Oh CM, Ryu D; Resources: Oh CM; Visualization: Oh CM; Writing - original draft: Oh CM, Ryu D, Cho S, Jang Y; Writing - review & editing: Jang Y.

diverse chaperons and proteases that facilitate communication with other organelles, termed mitochondria-cytosol-nucleus crosstalk.\(^5\) If damages in the mitochondria are not rescued, the disrupted mitochondria are engulfed by an autophagosome for lysosome degradation.\(^6\)

Recent studies revealed the significant role of mitochondrial dysfunction in heart disease and the emergence of mitochondrial function restoration as a novel therapeutic target.\(^7\) In this review, we discuss the MQC systems and their role in cardiac protection and heart failure development. We then describe novel drug candidates (urolithin A and spermidine) for the treatment of cardiovascular disease (CVD) by maintaining mitochondrial homeostasis and restoring mitochondrial function.

MITOCHONDRIAL QUALITY CONTROL SYSTEMS

Mitochondrial proteostasis
The mitochondria are a central hub of cellular metabolism and signaling. Therefore, keeping the proteomic integrity in the mitochondria is crucial for cell survival.\(^8\) To protect the heart under stressful conditions, protein homeostasis is maintained through several mechanisms or “proteostasis” within the mitochondria. Mitochondrial proteostasis includes mitochondrial-localized chaperons and proteases, degradation of bulk mitochondrial organelles, mitochondrial-nuclear communications, and transcellular signaling (e.g., mitokine signals) (Figure 1).\(^1,11\) To protect the mitochondrial proteome against reactive oxygen species (ROS) damage and misfolded protein toxicity, mitochondria have localized protective machines such as chaperones, antioxidant enzymes, and proteases within mitochondria. The key chaperones include mitochondrial Hsp70 (mtHsp70), mtHSP90, and the large chaperonin Hsp60/10 complex, which fold nascent polypeptides or repair misfolded proteins.\(^14,16\) Superoxide dismutase enzymes such as SOD2 in the mitochondrial matrix and SOD1 in the intermembrane space (IMS) protect the mitochondria from ROS damage.\(^17\) Several proteases in the mitochondrial matrix (e.g., LonP1 and ClpP) and within the IMS (e.g., m-AAA and i-AAA) degrade damaged mitochondrial proteins.\(^18\) In addition, mitochondrial dynamic processes such as mitochondrial fusion and fission also play a role in maintaining healthy mitochondria. Mitochondrial fusion dilutes the effects of small amounts of damage\(^19\) while mitochondrial fission separates damaged mitochondria from healthy mitochondria. Segregated mitochondria are subsequently degraded by mitophagy.\(^20\)

Only 13 proteins are encoded within the mtDNA, while 1,000–1,500 resident mitochondrial proteins are encoded by nuclear DNA.\(^20\) This implies that most mitochondrial proteins should be correctly folded within the cytoplasm and imported into the mitochondria.\(^22\) Therefore, vast communication between the mitochondria and other cellular compartments is expected. The mitochondrial unfolded protein response (UPR\(^\text{mt}\)) and mitophagy are two major mechanisms for maintaining mitochondrial proteostasis, which include intracellular communication, in the context of the cell.\(^22\)

Unfolded mitochondrial protein response
Poor quality mitochondria increase cellular oxidative stress and degenerative apoptosis signals leading to cell death.\(^23\) Disrupted mitochondrial proteostasis and dysfunction initiates a retrograde signaling pathway from the mitochondria to the nucleus. This retrograde signaling, known as UPR\(^\text{mt}\), initiates a transcriptional program to relieve mitochondrial stress.\(^24\) The UPR\(^\text{mt}\) is a coordinated response mediated by mitochondrial-
nuclear communications, triggered by mtDNA depletion or protein misfolding in the mitochondrial matrix.\textsuperscript{25} Although this pathway was discovered in mammalian cells, parts of its regulation mechanism have been discovered in worms. In \textit{Caenorhabditis elegans}, mitochondrial proteotoxicity reduces the mitochondrial import efficiency of a stress activated transcription factor, activating transcription factor associated with stress (ATFS)-1, which is the potential transcription factor mammalian ortholog of activating transcription factor (ATF) 4, ATF5, and C/EBP homologous protein.\textsuperscript{22} Under physiologic condition, ATFS-1 goes into the mitochondria and is degraded by a Lon protease.\textsuperscript{25} As a result of mitochondrial perturbation, mitochondrial import is compromised and allows ATFS-1 to be trafficked to the nucleus. Once there, it induces hundreds of genes associated with proteases, antioxidant enzymes, and genes involved in mitochondrial dynamics, protein import, and cellular metabolism.\textsuperscript{22}
Interestingly, there are significant differences in the mammalian UPR\textsuperscript{mt} signaling cascade compared to \textit{C. elegans}. For example, \textit{C. elegans} mitochondrial ClpP protease has a central role generating peptides and acting as a retrograde messenger by proteolyzing misfolded proteins. However, genetical ClpP depletion in the hearts of mice did not affect UPR\textsuperscript{mt} signaling.\textsuperscript{26}

In the mammalian mitochondria, ATF5 is a proposed mediator of UPR\textsuperscript{mt}.\textsuperscript{27} In previous studies, pharmacological induction of UPR\textsuperscript{mt} was found to play a role in protecting the heart of wild-type (WT) mice after ischemia-reperfusion (I/R) injury but was not involved in protecting ATF5 knockout mice hearts. Further RNA sequencing results revealed that UPR\textsuperscript{mt} induced ATF5-dependent pathway contributes to cardioprotection.\textsuperscript{28} Another possible additional main regulator of UPR\textsuperscript{mt} in mammals is ATF4. By treating HeLa cells with 4 therapeutic drugs (doxycycline, actinonin, FCCP, MitoBlokC-6) altering mitochondrial proteostasis and performing multi-omics analyses, Pedro M. et al. reported that ATF4 coordinates mitochondrial stress response.\textsuperscript{29} ATF4 is essential to maintain cell proliferation and protect the cell against mitochondrial stress; however, it is not involved in mtDNA metabolism.\textsuperscript{29}

\textbf{Mitophagy}

Mitophagy is a critical MQC mechanism in cardiac myocytes. Impaired mitophagy leads to accumulation of aberrant mitochondria, loss of myocytes, and contractile dysfunction.\textsuperscript{30} Mitophagy is defined as mitochondrial degradation through the macroautophagy pathway.\textsuperscript{23} This removal process is necessary for maintenance of the MQC systems. Selective removal of dysfunctional mitochondria is extremely complex and requires mitochondrial and cytosolic proteins to perform highly coordinated functions to maintain healthy mitochondria; this is essential for cell metabolism and survival.\textsuperscript{31} An important pathway in mitophagy is the PTEN-induced kinase 1 (PINK1)/Parkin pathway. Under physiologic conditions, the PINK1 is imported into the mitochondrial matrix to be degraded by LonPI. However, in membrane deficient mitochondria, PINK1 accumulates on the outer mitochondrial membrane.\textsuperscript{32} This leads to the recruitment of E3 ubiquitin ligase and Parkin from the cytosol and transference to the mitochondrial membrane (PINK1-dependent Parkin translocation), where Parkin initiates ubiquitination of multiple outer membrane proteins.\textsuperscript{32} Mitophagy also takes place through a Parkin-independent pathway. Some mitophagy receptor proteins on the mitochondrial outer membrane (e.g., BNIP3, FUNDC1, Bcl2-L-13, AMBRA1, and cardiolipin) bind to LC3 in a Parkin-independent manner.\textsuperscript{33} Under hypoxic conditions, BNIP3 promotes mitophagy and protects cells from oxidative damage.\textsuperscript{34} FUNDC1 interacts with LC3 to activate Parkin-independent mitophagy in response to hypoxia and hypoxic mitophagy in platelets protecting the heart from IR injury in the FUNDC1-dependent mitophagy.\textsuperscript{35} Bcl2-L-13 induces mitochondrial fragmentation and mitophagy in HEK293 cells.\textsuperscript{36} Cardiolipin, a phospholipid stabilizing OXPHOS complex, is synthesized in the mitochondrial inner membrane and translocated to the outer membrane, where it initiates mitophagy to protect the cell from cell apoptosis under mitochondrial stress conditions.\textsuperscript{11}

\textbf{MITOCHONDRIAL QUALITY CONTROL AND HEART DISEASE}

\textbf{UPR\textsuperscript{mt} and heart disease}

Nicotinamide riboside (NR) is well-known for boosting UPR\textsuperscript{mt} by augmenting NAD\textsuperscript{+} pools.\textsuperscript{37} Smyrnias et al.\textsuperscript{3} reported that UPR\textsuperscript{mt} boosting by NR improves heart function in the mice...
model of pressure overload-induced heart failure. Mice were treated with NR or a control vehicle for 3 days prior to subjecting them to transverse aortic constriction (TAC) surgery. At 1 week post TAC surgery, NR treated mice showed improved left ventricle (LV) function in the echocardiogram and reduced cardiomyocyte death in histologic analysis. Research from Xu et al. also reported a UPR mt boosting by choline-attenuated cardiac dysfunction in the rat model pressure overload-induced heart failure through the SIRT1-AMPK pathway. Aortic stenosis (AS) is the clinical model of chronic pressure overload. Myocardial tissue from AS patients showed that UPR mt mRNA marker levels increased in AS patients compared to control subjects. In the subgroup analysis of AS patients, UPR mt markers levels had a negative correlation with cardiomyocyte tissue death, fibrosis, and cardiac damage markers.

UPR mt activation also showed cardioprotective effects against heart I/R injury models. Wang et al. examined the role of UPR mt in perfused heart IR injury models with ATF5 knockout (KO) mouse. When the UPR mt was activated using oligomycin and doxycycline treatment, WT mice hearts exhibited significant improvement in post-IR functional recovery and infarct size. However, this protective effect was absent in ATF5 KO mouse hearts. Nicotinamide mononucleotide (NMN), a NAD+ boosting agent like NR, also exhibited cardioprotective effects in the IR injury model. Nadtochiy et al. reported that NMN pretreatment showed significant protection against IR injury (post-IR functional recovery: NMN, 42±7% vs. vehicle, 11±3%; infarct size: NMN, 34±4% vs. vehicle, 66±4%).

**Mitophagy and heart disease**

Mitophagy plays a key role in the removal of damaged mitochondria in response to several stresses such as hypoxia and cytosolic Ca2+ overload. Previous studies report that mitophagy has an essential role in the development of heart failure. Protein levels of PINK1 in LV heart samples from end stage HF patients were decreased compared with normal controls. Previous research indicates that PINK1 KO mice developed cardiac hypertrophy at 2 months of age, and loss of PINK1 increased infarct size after I/R injury. Parkin KO mice accumulated abnormal mitochondria with increasing age. Although young Parkin KO mice had normal cardiac function, these mice were more sensitive to myocardial infarction (MI) than WT mice; moreover, they possessed a reduced mitophagy, the accumulated swollen, and dysfunctional mitochondria within the heart of the MI rat model. Mitophagy also showed a protective role against pressure overload induced heart failure by TAC.

Diabetic cardiomyopathy (DCM) is a cardiac phenotype of diabetic patients. DCM is defined as the existence of abnormal myocardial structure and performance in the absence of additional cardiac risk factors. Diabetes-derived mitochondrial dysfunction has an essential role in DCM development. The DCM-affected mitochondria portray a dysregulation of Ca2+ handling, alternations in energy metabolism, and an increased oxidative stress. Mitophagy activation has shown protective effects against high fat diet (HFD)-induced DCM in mice studies. A study done by Tong et al. in Parkin KO mice reported that mitophagy was upregulated and there were severe cardiac hypertrophy and diastolic dysfunctions after mice consumption of HFD. Enhancing PINK1/Parkin-mediated mitophagy using melatonin has been found to decrease DCM-derived dysfunctional mitochondria in mice. Recent studies using animal models further reveal mitophagy role in heart disease (Table 1).
NOVEL CANDIDATES FOR MITOCHONDRIAL QUALITY CONTROL IN THE HEART

Urolithin A
Numerous studies have reported the beneficial effects of phytochemicals in metabolic disease, such as metabolic syndrome and CVD. Urolithin A is the well-known gut microbiota-generated small metabolite from pomegranate fruits. Natural compounds known as ellagitannins from pomegranate juice are hydrolyzed in the gut to release ellagic acid. Colonic microflora converts ellagic acid to urolithins and enter the systemic circulation. Ryu et al. reported that urolithin A improves mitochondrial proteostasis by inducing mitophagy. Urolithin A supplementation also extended lifespan in C. elegans and improved skeletal muscle function in mice.

The pomegranate fruit has shown beneficial effects in CVD. Pomegranate juice improves stress-induced myocardial ischemia in patients who have coronary heart disease and inhibits atherosclerosis development. These findings suggest potential benefits of urolithin A in cardiac myocytes which many studies have revealed throughout the years. In rodents, urolithin metabolites accumulate in the myocardium after urolithin A administration. Urolithin A activates mitophagy signal in cardiac myocytes and suppresses cardiac fibrosis, reduces cardiac tissue inflammation, and improves cardiac function in the streptozotocin-induced DCM rat model. Recent human clinical trials revealed that urolithin A also improves mitochondrial function in human skeletal muscle. These results suggest that urolithin A may improve mitochondrial and heart muscle function in CVD human patients.

Spermidine
Spermidine is a natural polyamine abundant in certain foods, such as rice bran, soybeans, aged cheese, mushrooms, and broccoli. This polyamine has shown beneficial effects in many diseases by improving mitochondrial function. Spermidine stimulates Ca\(^{2+}\) uptake in isolated mitochondria from mice liver, heart, and brain. In mice neuroblastoma cells, spermidine treatment protects mitochondrial damage, stabilizes mitochondrial genome and membrane potential, and reduces apoptosis due to D-galactose (gal)-induced stress. A combination of spermidine and exercise rescues skeletal muscle atrophy in D-gal-induced aging rats.

In addition, spermidine portrayed cardiovascular protective effects in previous studies. Spermidine feeding led to a 10% increase in the median lifespan of C57BL/6J mice and

Table 1. Genetically modified mice and their cardiac phenotypes

| Model     | Mitophagy | Phenotypes                                                                 | Ref                    |
|-----------|-----------|-----------------------------------------------------------------------------|------------------------|
| Parkin KO | Decreased | Increased sensitivity to MI and doxorubicin exposure, accumulation of dysfunctional mitochondria, and oxidative damage with age, reduced life span | 43(48-50)              |
| Parkin TG | Increased | Increased life span, preserved cardiac function with aging                  | 42(48-54)              |
| PINK1 KO  | NA        | Mitochondrial dysfunction, cardiomyopathy, increased sensitivity to I/R      | 48(44-46)              |
| BNIP3 KO  | NA        | Decreased apoptosis and cardiac remodeling in response to I/R               | 43(53)                 |
| BNIP3 TG  | NA        | Increased sensitivity to MI, increased apoptosis                             | 43(53)                 |
| NIX KO    | NA        | Decreased cardiac remodeling and preserved cardiac function in response to pressure overload | 43(53)                 |
| NIX TG    | NA        | Ventricular dilation, reduced cardiac function                               | 43(53)                 |

Reproduced from “Mitophagy and heart failure.” By Shires and Gustafsson, Journal of Molecular Medicine 2015;93:253-62. I/R = ischemia-reperfusion; KO = knock out; MI = myocardial infarction; NA = not assessed; I/R = ischemia-reperfusion; TG = transgenic.
delayed heart failure progression in Dahl rats. In similar studies, spermidine reduced inflammation, induced autophagy and mitophagy, increased mitochondrial respiration in the heart, and improved heart function in aged mice. In a human cohort study, spermidine levels declined with aging, and spermidine intake showed inverse association with heart failure, acute coronary artery disease, stroke, and death due to vascular disease. Therefore, spermidine supplementation shows promise for CVD prevention and treatment.

CONCLUSIONS

Mitochondria have numerous roles essential for energy metabolism, cell cycle control, cell development, immune response, and cell death. Scientists regard the mitochondria as a central platform in the execution of diverse cellular events and see vast potential in using mitochondrial dysfunction as a therapeutic target for human diseases such as CVD. Targeting of UPR, mitophagy, or both, as a novel therapeutic strategy with optimistic potential in improving human heart disease. Future research focusing on the machinery regulating mitochondrial proteostasis under various stress conditions is needed to unveil the new molecular pathways of MQC.

Drugs targeting the mitochondria such as NR and spermidine have already shown good clinical activity and beneficial effects in age-related human disease. Urolithin A also showed beneficial effects in elderly skeletal muscle improvement. These clinical data provide good promise and excitement over novel therapeutic options against heart disease as discussed within this review. Further researches aimed at identifying new compounds enhancing mitochondrial proteostasis and long-term clinical studies are needed for the prevention of heart disease and the recovery of heart function in CVD patients.

REFERENCES

1. Zhou R, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest 2018;128:3716-26.
2. Pickles S, Vigie P, Youle RJ. Mitophagy and quality control mechanisms in mitochondrial maintenance. Curr Biol 2018;28:R170-85.
3. Smyrnias I, Gray SP, Okonko DO, et al. Cardioprotective effect of the mitochondrial unfolded protein response during chronic pressure overload. J Am Coll Cardiol 2019;73:1795-806.
4. Campos JC, Bozi LH, Bechara LR, Lima VM, Ferreira JC. Mitochondrial quality control in cardiac diseases. Front Physiol 2016;7:479.
5. Guaragnella N, Coyne LP, Chen XJ, Giannattasio S. Mitochondria-cytosol-nucleus crosstalk: learning from Saccharomyces cerevisiae. FEMS Yeast Res 2018;18:foy088.
6. Goldman SJ, Taylor R, Zhang Y, Jin S. Autophagy and the degradation of mitochondria. Mitochondrion 2010;10:309-15.
7. Brown DA, Perry JB, Allen ME, et al. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol 2017;14:238-50.
8. Kuzmicic J, Del Campo A, López-Crisostoy C, et al. Mitochondrial dynamics: a potential new therapeutic target for heart failure. Rev Esp Cardiol 2011;64:916-23.
9. Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. *J Am Coll Cardiol* 2013;61:599-610.

10. Szklarczyk R, Nooteboom M, Osiewacz HD. Control of mitochondrial integrity in ageing and disease. *Philos Trans R Soc Lond B Biol Sci* 2014;369:20130439.

11. Ren M, Phoon CK, Schlame M. Metabolism and function of mitochondrial cardiolipin. *Prog Lipid Res* 2014;55:1-16.

12. Moehle EA, Shen K, Dillin A. Mitochondrial proteostasis in the context of cellular and organismal health and aging. *J Biol Chem* 2019;294:5396-407.

13. Yi HS. Implications of mitochondrial unfolded protein response and mitokines: a perspective on fatty liver diseases. *Endocrinol Metab (Seoul)* 2019;34:39-46.

14. Ostermann J, Horwich AL, Neupert W, Hartl FU. Protein folding in mitochondria requires complex formation with hsp60 and ATP hydrolysis. *Nature* 1989;341:125-30.

15. Höhfeld J, Hartl FU. Role of the chaperonin cofactor Hsp10 in protein folding and sorting in yeast mitochondria. *J Cell Biol* 1994;126:305-15.

16. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. *J Biol Chem* 2000;275:3305-12.

17. Wang Y, Branicky R, Noë A, Hekimi S. Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling. *J Cell Biol* 2018;217:1915-28.

18. Baker MJ, Tatsuta T, Langer T. Quality control of mitochondrial proteostasis. *Cold Spring Harb Perspect Biol* 2011;3:a007559.

19. Tondera D, Grandemange S, Jourdain A, et al. SLP-2 is required for stress-induced mitochondrial hyperfusion. *EMBO J* 2009;28:1589-600.

20. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. *Science* 2012;337:1062-5.

21. Chinnery PF, Hudson G. Mitochondrial genetics. *Br Med Bull* 2013;106:135-59.

22. Melber A, Haynes CM. UPR\textsuperscript{mt} regulation and output: a stress response mediated by mitochondrial-nuclear communication. *Cell Res* 2018;28:281-95.

23. Zhang J. Autophagy and mitophagy in cellular damage control. *Redox Biol* 2013;1:19-23.

24. Jang JY, Blum A, Liu J, Finkel T. The role of mitochondria in aging. *J Clin Invest* 2018;128:3662-70.

25. Nargund AM, Pellegrino MW, Fiorese CJ, Baker BM, Haynes CM. Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation. *Science* 2012;337:587-90.

26. Seiferling D, Szczepanowska K, Becker C, et al. Loss of CLPP alleviates mitochondrial cardiomyopathy without affecting the mammalian UPR\textsuperscript{mt}. *EMBO Rep* 2016;17:953-64.

27. Fiorese CJ, Schulz AM, Lin YF, Rosin N, Pellegrino MW, Haynes CM. The transcription factor ATF5 mediates a mammalian mitochondrial UPR. *Curr Biol* 2016;26:2037-43.

28. Wang YT, Lim Y, McCall MN, et al. Cardioprotection by the mitochondrial unfolded protein response requires ATF5. *Am J Physiol Heart Circ Physiol* 2019;317:H472-8.

29. Quiroš PM, Prado MA, Zamboni N, et al. Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response in mammals. *J Cell Biol* 2017;216:2027-45.

https://e-kcj.org

https://doi.org/10.4070/kcj.2019.0416

402
30. Shires SE, Gustafsson ÅB. Mitophagy and heart failure. *J Mol Med (Berl)* 2015;93:253-62.

31. Jin SM, Lazarou M, Wang C, Kane LA, Narendra DP, Youle RJ. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *J Cell Biol* 2010;191:933-42.

32. Chan NC, Salazar AM, Pham AH, et al. Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. *Hum Mol Genet* 2017;7:1407-24.

33. Nah J, Miyamoto S, Sadoshima J. Mitophagy as a protective mechanism against myocardial stress. *Compr Physiol* 2017;7:1407-24.

34. Zhang H, Bosch-Marce M, Shimoda LA, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. *J Biol Chem* 2008;283:10892-903.

35. Zhang W, Ren H, Xu C, et al. Hypoxic mitophagy regulates mitochondrial quality and platelet activation and determines severity of I/R heart injury. *eLife* 2016;5:e21407.

36. Murakawa T, Yamaguchi O, Hashimoto A, et al. Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates mitophagy and mitochondrial fragmentation. *Nat Commun* 2015;6:7527.

37. Jovaisaite V, Mouchiroud L, Auwerx J. The mitochondrial unfolded protein response, a conserved stress response pathway with implications in health and disease. *J Exp Biol* 2014;217:137-43.

38. Xu M, Xue RQ, Lu Y, et al. Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway. *Cardiovasc Res* 2019;115:530-45.

39. Yarbrough WM, Mukherjee R, Ikonomidis JS, Zile MR, Spinale FG. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. *J Thorac Cardiovasc Surg* 2012;143:656-64.

40. Wang YT, Lim Y, McCall MN, Haynes CM, Nehrke KW, Brookes PS. Cardioprotection by the mitochondrial unfolded protein response (UPRmt) is mediated by activating transcription factor 5 (ATF5). *bioRxiv* 2018:344606.

41. Nadtochiy SM, Wang YT, Nehke K, Munger J, Brookes PS. Cardioprotection by nicotinamide mononucleotide (NMN): involvement of glycolysis and acidic pH. *J Mol Cell Cardiol* 2018;121:155-62.

42. Bravo-San Pedro JM, Kroemer G, Galluzzi L. Autophagy and mitophagy in cardiovascular disease. *Circ Res* 2017;120:1812-24.

43. Billia F, Hauck L, Konceny F, Rao V, Shen J, Mak TW. PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function. *Proc Natl Acad Sci U S A* 2011;108:9572-7.

44. Siddall HK, Yellon DM, Ong SB, et al. Loss of PINK1 increases the heart’s vulnerability to ischemia-reperfusion injury. *PLoS One* 2013;8:e62400.

45. Kubli DA, Zhang X, Lee Y, et al. Parkin protein deficiency exacerbates cardiac injury and reduces survival following myocardial infarction. *J Biol Chem* 2013;288:915-26.

46. Shirakabe A, Zhai P, Ikeda Y, et al. Drp1-dependent mitochondrial autophagy plays a protective role against pressure overload-induced mitochondrial dysfunction and heart failure. *Circulation* 2016;133:1249-63.

47. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. *Circ Res* 2018;122:624-38.

48. Liang Q, Kobayashi S. Mitochondrial quality control in the diabetic heart. *J Mol Cell Cardiol* 2016;95:57-69.

49. Galloway CA, Yoon Y. Mitochondrial dynamics in diabetic cardiomyopathy. *Antioxid Redox Signal* 2015;22:1545-62.
50. Tong M, Saito T, Zhai P, et al. Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy. *Circ Res* 2019;124:1360-71. [PUBMED](https://doi.org/10.1161/CircRes.118.317632) [CROSSREF](https://doi.org/10.1161/CircRes.118.317632)

51. Wang S, Zhao Z, Feng X, et al. Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition. *J Cell Mol Med* 2018;22:5132-44. [PUBMED](https://doi.org/10.1111/jcmm.14144) [CROSSREF](https://doi.org/10.1111/jcmm.14144)

52. Hoshino A, Mita Y, Okawa Y, et al. Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. *Nat Commun* 2013;4:2308. [PUBMED](https://doi.org/10.1038/ncomms3369) [CROSSREF](https://doi.org/10.1038/ncomms3369)

53. Kubli DA, Quinsay MN, Gustafsson ÅB. Parkin deficiency results in accumulation of abnormal mitochondria in aging myocytes. *Commun Integr Biol* 2013;6:e24511. [PUBMED](https://doi.org/10.4161/cib.26216) [CROSSREF](https://doi.org/10.4161/cib.26216)

54. Rana A, Rera M, Walker DW. Parkin overexpression during aging reduces proteotoxicity, alters mitochondrial dynamics, and extends lifespan. *Proc Natl Acad Sci USA* 2013;110:8638-43. [PUBMED](https://doi.org/10.1073/pnas.1313731110) [CROSSREF](https://doi.org/10.1073/pnas.1313731110)

55. Diwan A, Krenz M, Syed FM, et al. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. *J Clin Invest* 2007;117:2825-33. [PUBMED](https://doi.org/10.1172/JCI31097) [CROSSREF](https://doi.org/10.1172/JCI31097)

56. Yussman MG, Toyokawa T, Odley A, et al. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. *Nat Med* 2002;8:725-30. [PUBMED](https://doi.org/10.1016/S1096-3886(02)00183-2) [CROSSREF](https://doi.org/10.1016/S1096-3886(02)00183-2)

57. Cicero AF, Colletti A. Role of phytochemicals in the management of metabolic syndrome. *Phytomedicine* 2016;23:1134-44. [PUBMED](https://doi.org/10.1016/j.phymed.2015.11.012) [CROSSREF](https://doi.org/10.1016/j.phymed.2015.11.012)

58. Vasanthi HR, ShriShriMal N, Das DK. Phytochemicals from plants to combat cardiovascular disease. *Curr Med Chem* 2012;19:2242-51. [PUBMED](https://doi.org/10.2174/09298671279971919224251) [CROSSREF](https://doi.org/10.2174/09298671279971919224251)

59. Vicinanza R, Zhang Y, Henning SM, Heber D. Pomegranate juice metabolites, ellagic acid and urolithin a, synergistically inhibit androgen-independent prostate cancer cell growth via distinct effects on cell cycle control and apoptosis. *Evid Based Complement Alternat Med* 2013;2013:247504. [PUBMED](https://doi.org/10.1155/2013/247504) [CROSSREF](https://doi.org/10.1155/2013/247504)

60. Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in *C. elegans* and increases muscle function in rodents. *Nat Med* 2016;22:879-88. [PUBMED](https://doi.org/10.1038/nm.3973) [CROSSREF](https://doi.org/10.1038/nm.3973)

61. Sumner MD, Elliott-Eller M, Weidner G, et al. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. *Am J Cardiol* 2005;96:810-4. [PUBMED](https://doi.org/10.1016/j.amjcard.2005.07.027) [CROSSREF](https://doi.org/10.1016/j.amjcard.2005.07.027)

62. Aviram M, Rosenblat M. Pomegranate protection against cardiovascular diseases. *Evid Based Complement Alternat Med* 2012;2012:382763. [PUBMED](https://doi.org/10.1155/2012/382763) [CROSSREF](https://doi.org/10.1155/2012/382763)

63. Savi M, Bocchi L, Mena P, et al. In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats. *Cardiovasc Diabetol* 2017;16:80. [PUBMED](https://doi.org/10.1186/s12933-017-0485-0) [CROSSREF](https://doi.org/10.1186/s12933-017-0485-0)

64. Wu X, Zhu X, Zhou Y. Urolithin A suppress cardiac fibrosis via autophagy pathway in the diabetic cardiomyopathy. *Circ Res* 2019;125:A531. [CROSSREF](https://doi.org/10.1161/CIRCRESAHA.119.319079)

65. Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. *Nat Metab* 2019;1:595-603. [CROSSREF](https://doi.org/10.1038/s42255-019-0041-y)

66. Larquè E, Sabater-Molina M, Zamora S. Biological significance of dietary polyamines. *Nutrition* 2007;23:87-95. [PUBMED](https://doi.org/10.1016/j.nut.2006.10.024) [CROSSREF](https://doi.org/10.1016/j.nut.2006.10.024)

67. Lenzen S, Hickethier R, Panten U. Interactions between spermine and Mg2+ on mitochondrial Ca2+ transport. *J Biol Chem* 1986;261:16478-83. [PUBMED](https://doi.org/10.1016/S0021-9258(17)30202-7) [CROSSREF](https://doi.org/10.1016/S0021-9258(17)30202-7)

68. Jing YH, Yan JL, Wang QJ, et al. Spermidine ameliorates the neuronal aging by improving the mitochondrial function in vitro. *Exp Gerontol* 2018;108:77-86. [PUBMED](https://doi.org/10.1016/j.exger.2018.02.009) [CROSSREF](https://doi.org/10.1016/j.exger.2018.02.009)
69. Fan J, Yang X, Li J, et al. Spermidine coupled with exercise rescues skeletal muscle atrophy from D-gal-induced aging rats through enhanced autophagy and reduced apoptosis via AMPK-FOXO3a signal pathway. *Oncotarget* 2017;8:17475-90.

70. Eisenberg T, Abdellatif M, Schroeder S, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. *Nat Med* 2016;22:1428-38.

71. Tong D, Hill JA. Spermidine promotes cardioprotective autophagy. *Circ Res* 2017;120:1229-31.

72. Madeo F, Bauer MA, Carmona-Gutierrez D, Kroemer G. Spermidine: a physiological autophagy inducer acting as an anti-aging vitamin in humans? *Autophagy* 2019;15:165-8.

73. Stegemann C, Pechlaner R, Willeit P, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. *Circulation* 2014;129:1821-31.

74. McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. *Curr Biol* 2006;16:R551-60.

75. Madeo F, Carmona-Gutierrez D, Kepp O, Kroemer G. Spermidine delays aging in humans. *Aging (Albany NY)* 2018;10:2209-11.

76. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures in aged subjects: a placebo-controlled, randomized trial. *bioRxiv* 2019:680462.